European Journal of Clinical Pharmacology

, Volume 13, Issue 6, pp 435–438 | Cite as

The effects of chronic alcohol ingestion and alcoholic liver disease on binding of drugs to serum proteins

  • M. J. Brodie
  • S. Boobis


The binding of salicylate, sulphadiazine and phenylbutazone in whole serum of patients with alcohol-induced liver disease has been compared to that of chronic alcoholics with no evidence of liver disease, and normal healthy subjects. Binding of all three drugs was normal in the chronic alcoholic group, but decreased in patients with alcoholic liver disease. In subjects with alcoholic hepatitis, this decrease appeared to be correlated with variations in serum bilirubin and albumin levels. These observations may be of clinical relevance to the distribution of drugs in alcoholic patients with accompanying hepatic disease.

Key words

Drug-protein binding liver disease alcohol bilirubin albumin 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Affrime, M., Reidenberg, M. M.: The binding of drugs to plasma from patients with cirrhosis. Pharmacologist15, 207 (1973)Google Scholar
  2. Affrime, M., Reidenberg, M. M.: The protein binding of some drugs in plasma from patients with alcoholic liver disease. Europ. J. Clin. Pharmacol.8, 267–269 (1975)Google Scholar
  3. Dromgoole, S. H.: The binding capacity of albumin and renal disease. J. Pharmacol. Exp. Ther.191, 318–323 (1974)Google Scholar
  4. Hooper, W. D., Bochner, F., Eadie, M. J., Tyrer, J. H.: Plasma protein binding of diphenylhydantoin. Clin. Pharmacol. Ther.15, 276–282 (1974)Google Scholar
  5. Hooper, W. D., Dubetz, D. K., Bochner, F., Cotter, L. M., Smith, G. A., Eadie, M. J., Tyrer, J. H.: Plasma protein binding of carbamazepine. Clin. Pharmacol. Ther.17, 433–440 (1975)Google Scholar
  6. Koch-Weser, J.: Serum drug concentrations as therapeutic guides. New Eng. J. Med.287, 222–231 (1972)Google Scholar
  7. Olsen, G. D., Bennett, W. M., Porter, G. A.: Morphine and phenytoin binding to plasma protein in renal and hepatic failure. Clin. Pharmacol. Ther.17, 677–685 (1975)Google Scholar
  8. Powell, L. W., Axelsen, E.: Corticosteroids in liver disease: Studies on the biological conversion of prednisone to prednisolone and plasma protein binding. Gut13, 690–696 (1972)Google Scholar
  9. Reidenberg, M. M.: Effect of disease states on plasma protein binding of drugs. Med. Clin. N. Amer.58, 1103–1109 (1974)Google Scholar
  10. Reidenberg, M. M., Affrime, M.: Influence of disease states on binding of drugs to plasma proteins. Ann. N. Y. Acad. Sci.226, 115–126 (1973)Google Scholar
  11. Thiessen, J. J., Sellers, E. M., Denbeigh, P., Dolman, L.: Plasma protein binding of diazepam and tolbutamide in chronic alcholics. J. Clin. Pharmacol.16, 345–351 (1976)Google Scholar
  12. Wallace, S., Brodie, M. J.: Decreased drug binding in serum from patients with chronic hepatic disease. Europ. J. Clin. Pharmacol.9, 429–432 (1976)Google Scholar

Copyright information

© Springer-Verlag 1978

Authors and Affiliations

  • M. J. Brodie
    • 1
  • S. Boobis
    • 2
  1. 1.Department of Materia Medica University of GlasgowStobhill General HospitalGlasgowScotland
  2. 2.Department of Clinical Pharmacology St Bartholomew's HospitalLondonUK

Personalised recommendations